Phio Pharmaceuticals Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated July 25, 2025, reports on a capital raise transaction by Phio Pharmaceuticals Corp. (PHIO). The company entered into inducement letter agreements with holders of existing warrants to facilitate the immediate exercise of those warrants and the issuance of new warrants. The transaction closed on July 28, 2025.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $2.5 million from the exercise of existing warrants.
- Warrant Exercise Details:
- 100,000 shares exercised at $2.00 per share.
- 828,596 shares exercised at a reduced price of $2.485 per share.
- New Warrant Issuance:
- Series J Warrants: Up to 318,596 shares at $2.485/share; 5-year term.
- Series K Warrants: Up to 1,538,596 shares at $2.485/share; 24-month term.
- Transaction Costs:
- Placement Agent (H.C. Wainwright & Co., LLC): 7.5% cash fee + 1.0% management fee on gross proceeds.
- Non-accountable expenses: $50,000.
- Clearing fees: $15,950.
- Placement Agent Warrants: 69,645 shares issued as compensation (7.5% of exercised warrants).
Note: The filing does not provide specific figures for revenue, net income, operating cash flow, total debt, or liquidity ratios as this is a current report on a specific event, not a periodic financial statement.
Material Changes and Agreements
The primary material change is the reduction of the exercise price for 828,596 existing warrants from their original range ($2.00–$3.00) to $2.485 per share to induce immediate exercise. In exchange, holders received new unregistered warrants (Series J and K) and paid an additional $0.125 per new warrant (totaling $232,149). The company agreed to a 15-day lock-up period on issuing new equity or filing new registration statements following the closing.
Outlook, Risks, and Contingencies
- Registration Obligation: The company must file a resale registration statement for the new warrant shares within 20 calendar days of the agreement date.
- Dilution Risk: The issuance of new warrants (Series J and K) and placement agent warrants creates potential future dilution if exercised.
- Future Fees: Additional fees and warrant issuances to the placement agent are contingent upon the future cash exercise of the new Series J and K warrants.
Investor Verification Checklist
- Verify the effective date of the Resale Registration Statement to confirm the start of the warrant terms.
- Confirm the exact net proceeds after deducting the 8.5% total fee (7.5% + 1.0%) and fixed expenses from the $2.5 million gross.
- Review the attached exhibits (10.1, 4.1, 4.2) for specific terms regarding the "blackout" period and warrant exercise conditions.
- Monitor the company's cash burn rate to assess how the $2.5 million infusion impacts the runway for clinical development.